Hermann Bujard - Tet System and malaria vaccine candidate

The well-known molecular biologist Professor Hermann Bujard drives research in the most diverse fields. ...

Online PR News – 17-June-2010 – – Almost all leading pharmaceutical companies and countless research laboratories use Tet Systems in their daily work. The inventor Professor Hermann Bujard and his team created a standard microbiological tool that targets the on/off switch of genes.

A new invention, which optimizes the Tet promotors, and thus further improves the application of the Tet technology, has been commercialized by the Technologie-Lizenz-Büro GmbH in Karlsruhe, Germany. This patent commercialization agency acts on behalf of the University of Heidelberg, where Bujard became professor of molecular genetics in 1970, and where he was spearheaded for establishing the Centre for Molecular Biology (ZMBH) in the 1980s. "The latest invention by Professor Bujard has the clear potential of being another commercial success", says Dr Uta Weirich, TLB Innovation Manager responsible for this project.

Hermann Bujard intends to invest some of the private income generated by the Tet patents in a project for which he is strongly committed to for the past two decades, both scientifically as well as for humanitarian reasons: The development and testing of a new vaccine candidate for longer term protection against malaria tropica, the most serious form of malaria for which there is no vaccine available at present. After his retirement from the directorship of the European Molecular Biology Organization (EMBO) in Heidelberg until the end of 2009, Hermann Bujard has returned to the university. There, together with his collaborator of many years Professor Michael Lanzer, he is continuing his research for vaccine.

A new invention which complements Bujard"s existing malaria patent portfolio was claimed by the University based on an assessment of its patentability and its commercial potential by TLB.

The production of the vaccine candidates is under preparation and Bujard expects that the first phase of clinical studies will start in Heidelberg as early as 2010.
About the Technologie-Lizenz-Büro (TLB) GmbH:
TLB is the commercialization agency for inventions from universities and other research institutions in the German State of Baden-Wuerttemberg. TLB's Innovation Managers bridge the gap between science and industry and offer a complete range of services from advising inventors and managing patent applications, to negotiating license agreements. TLB's broad patent portfolio mainly includes technologies in the following sectors, Energy, Measurement and Instrumentation, Microsystems, Materials, Medical Technologies, Pharmaceuticals, Chemistry, Biotechnology and Information and Communications Technology (ICT).

Technologie-Lizenz-Büro (TLB) der Baden-Württembergischen Hochschulen GmbH
Dr. Uta Weirich
Ettlinger Straße 25
76137 Karlsruhe, Germany
+49-721 79004-0



Dr. Kratt & Schurr PartnG
Dr. Regina Kratt
Sophienstr. 136
Karlsruhe, Germany
+49-721 831421-0